Extended-spectrum beta-lactamase production and multi-drug resistance among Enterobacteriaceae isolated in Addis Ababa, Ethiopia

Antimicrobial Resistance and Infection Control
Dejenie Shiferaw TekluKassu Desta Tullu

Abstract

The global emergence and spread of extended-spectrum beta-lactamases (ESBLs) producing Enterobacteriaceae have been threatening the ability to treat an infection. Hence, this study aimed to determine the prevalence of ESBL-producing and multi-drug resistance (MDR) Enterobacteriaceae (ESBLs-E) from different clinical specimens in Addis Ababa, Ethiopia. A cross-sectional study was conducted from January 1 to May 30, 2017. A total of 426 Enterobacteriaceae isolates were identified from clinical specimens. The isolates were collected from four laboratories. Antimicrobial susceptibility testing was performed using the Kirby-Bauer disk diffusion method on Muller Hinton agar (MHA). All Enterobacteriaceae were screened for ESBLs production using cefotaxime and ceftazidime as per CLSI guideline. Each ESBL screening positive Enterobacteriaceae were confirmed by a combination disk test (CDT). Data were entered and analyzed by using SPSS version-20. The most frequent Enterobacteriaceae were E. coli 228 (53.5%) and K. pneumoniae 103 (24.1%). The magnitude of ESBLs-E was 57.7% (246/426). The highest frequencies of ESBLs-E were observed in blood specimesns (84.4%) and the highest ESBLs production was observed in K. pneumoniae (85.4%). The hig...Continue Reading

References

Sep 1, 1991·Antimicrobial Agents and Chemotherapy·G A Jacoby, A A Medeiros
Jan 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A A Medeiros
Oct 13, 2004·BMC Public Health·Bjørn BlombergNina Langeland
Apr 28, 2005·Antimicrobial Agents and Chemotherapy·Mitchell J SchwaberYehuda Carmeli
Oct 15, 2005·Clinical Microbiology Reviews·David L Paterson, Robert A Bonomo
Jun 1, 2006·The American Journal of Medicine·David L Paterson
Oct 3, 2006·Expert Review of Anti-infective Therapy·Helen Giamarellou
Dec 25, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R CantónT M Coque
Feb 23, 2008·The Lancet Infectious Diseases·Johann D D Pitout, Kevin B Laupland
Dec 7, 2010·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Nevine FamMarie-Hélène Nicolas-Chanoine
Dec 7, 2010·International Journal of Antimicrobial Agents·Timothy R Walsh
Mar 29, 2014·Journal of Natural Science, Biology, and Medicine·Nema ShashwatiA G Dhanvijay
May 22, 2016·Infectious Disease Clinics of North America·Amos AdlerDror Marchaim
May 26, 2016·International Journal of Medical Microbiology : IJMM·Daniel EibachJürgen May
Feb 10, 2017·Infection and Drug Resistance·Melese Hailu LegeseDaniel Asrat

❮ Previous
Next ❯

Citations

Dec 12, 2020·Antimicrobial Resistance and Infection Control·Ebtisam S MohamedSoha S Abdelrahim
Apr 17, 2021·International Journal of Microbiology·Teklehaimanot KirosDebaka Belete
Jun 26, 2021·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Nongcebo Z Z MalingaLinda A Bester
Jul 2, 2021·BioMed Research International·Saba Gebremichael TekeleSamuel Kinde Birru
Jun 16, 2021·Journal of Global Antimicrobial Resistance·Tsegaye Alemayehu
Oct 7, 2021·Expert Review of Anti-infective Therapy·Mitra AhmadiTaher Mohammadian
Nov 15, 2021·Journal of Global Antimicrobial Resistance·Tsegaye SewunetChristian G Giske

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Related Feeds

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.